Fulcrum Therapeutics, Inc. announced that Esther Rajavelu has resigned from her position as chief financial officer, effective April 21, 2023. Ms. Rajavelu will serve in a consulting role to ensure the continuity of the company's financial operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.64 USD | -0.78% | -3.41% | +13.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.19% | 475M | |
+44.48% | 55.07B | |
+44.47% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics, Inc. Announces Resignation of Esther Rajavelu as Chief Financial Officer, Effective April 21, 2023